Clovis Oncology (CLVS) Trades Higher in Sympathy with TESARO (TSRO)

October 10, 2016 1:24 PM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Gains in Clovis Oncology (NASDAQ: CLVS) Monday were tied to data from PARP inhibitor peer TESARO (NASDAQ: TSRO). Earlier TESARO and ENGOT, the European Network for Gynaecological Oncological Trial groups, announced the presentation of the niraparib Phase 3 ENGOT-OV16/NOVA clinical trial results at the ESMO 2016 Congress.

Shares of TESARO surged over 20%, while Clovis gained about 8%.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Trader Talk

Add Your Comment